INTENSITY THERAPEUTICS (INTS) CFO Joseph Talamo Receives Award

What Happened

Joseph Talamo, Chief Financial Officer of Intensity Therapeutics, Inc. (INTS), was granted a derivative award covering 34,000 shares on July 16, 2026. The Form 4 shows the acquisition as a derivative award (transaction code A) with an acquisition amount reported as $0. This is an equity compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-16
• Transaction type/code: Award/Grant (A); derivative award of 34,000 shares
• Price reported: $0.00 (acquisition value shown as $0 on the filing)
• Shares owned after transaction: not disclosed in the provided filing
• Vesting: vests in four equal annual installments beginning July 16, 2027, subject to continued service (footnote)
• Filing date: 2026-07-20 (filed 4 days after the transaction; this exceeds the typical 2-business-day Form 4 deadline and may be late)

Context

This filing documents an equity compensation grant (options/awards) to the CFO. Derivative awards often show $0 in the acquisition column because no cash was exchanged at grant; the eventual value depends on the award's exercise price and future company stock performance. Such grants are common as part of executive compensation and do not in themselves indicate an insider buying or selling shares on the market.